"Today, more than 95 per cent of Australians living with cystic fibrosis now have access to a CFTR modulator,” said Elisha Whitfield, Senior Country Manager of Vertex Pharmaceuticals Australia and New Zealand.
Vertex announces PBS listing of new once-daily treatment for cystic fibrosis
February 1, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Another potential turning point for immunotherapy access in Australia
February 1, 2026 - - Latest News -
Better Access Australia’s plan to make care fair, affordable and accountable
February 1, 2026 - - Latest News -
Pfizer calls for Budget shift, citing missed medicines and the impact of lost productivity
February 1, 2026 - - Latest News -
Vertex announces PBS listing of new once-daily treatment for cystic fibrosis
February 1, 2026 - - Latest News -
The 'Dispatched' Podcast - Episode 2, Series 5
January 30, 2026 - - Podcast -
New long-term data suggest sustained benefit of Eisai therapy in early Alzheimer’s Disease
January 30, 2026 - - Latest News -
Amgen announces leadership transition for Australia and New Zealand
January 30, 2026 - - Latest News

